The curability of breast cancer: Present and future

European Journal of Cancer, Supplement

Volumn 1, Issue 1, 2003, Pages 24-34

  Hortobagyi, G N ^a  

^a Box 424 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; RALOXIFENE; RETINOID; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 2442542626     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00003-X     Document Type: Article

References (119)

1. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. Ca Cancer J. Clin. 50:2000;7-33
2. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. Ca. Cancer J. Clin. 49:1999;33-64
3. Wingo P.A., Ries L.A., Giovino G.A., et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J. Natl. Cancer Inst. 91:1999;675-690
4. Gatta G., Capocaccia R., Coleman M.P., et al. Toward a comparison of survival in American and European cancer patients. Cancer. 89:2000;893-900
5. Mettlin C. Global breast cancer mortality statistics. Ca. Cancer J. Clin. 49:1999;138-144
6. Kerlikowske K., Grady D., Rubin S.M., Sandrock C., Ernster V.L. Efficacy of screening mammography. A meta-analysis. JAMA. 273:1995;149-154
7. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer. an overview of the randomised trials Lancet. 352:1998;930-942
8. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467
9. Early Breast Cancer Trialists' Collaborative Group Ovarian ablation in early breast cancer. overview of the randomised trials Lancet. 348:1996;1189-1196
10. Phillips A.J. A comparison of treated and untreated cases of cancer of the breast. Br. J. Cancer. 13:1959;20-25
11. Baum M. The curability of breast cancer. Br. Med. J. 1:1976;439-442
12. Brinkley D., Haybittle J.L. The curability of breast cancer. World J. Surg. 1:1977;287-289
13. Robbins G.F., Berg J. Curability of patients with invasive breast carcinoma based on a 30-year study. World J. Surg. 1:1977;284-286
14. Jasmin C. Tumor stem cells and the curability of early human breast cancer. Recent Results Cancer Res. 127:1993;7-12
15. Kerr G.R., Kunkler I.H.,.Langlands A.O., Rodger A. (In)curability of breast cancer. a 30-year report of a series of 3933 cases Breast. 7:1998;90-94
16. Whitney D.G., Smith D.G., Szilagyi D.E. Meaning of five-year cure in cancer of the breast. Arch. Surg. 88:1964;637-644
17. Langlands A.O., Pocock S.J., Kerr G.R., Gore S.M. Long-term survival of patients with breast cancer. a study of the curability of the disease Br. Med. J. 2:1979;1247-1251
18. Brinkley D., Haybittle J.L. Long-term survival of women with breast cancer. Lancet. 1(8386):1984;1118
19. Wade P. Untreated carcinoma of the breast. Br. J. Radiol. 19:1946;272-280
20. Bloom H.J. The natural history of untreated breast cancer. Ann. NY Acad. Sci. 114:1964;747-754
21. Bloom H.J.G., Richardson W.W., Harries E.J. Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy. Br. Med. J. 2:1962;213-221
22. Satariano W.A., Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann. Intern. Med. 120:1994;104-110
23. Taplin S.H., Barlow W., Urban N., et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J. Natl. Cancer Inst. 87:1995;417-426
24. Schrijvers C.T., Coebergh J.W., Mackenbach J.P. Socioeconomic status and comorbidity among newly diagnosed cancer patients. Cancer. 80:1997;1482-1488
25. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol. 16:1998;1582-1587
26. Repetto L., Venturino A., Vercelli M., et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer. 82:1998;760-765
27. Nemoto T., Vana J., Bedwani R.N., Baker H.W., McGregor F.H., Murphy G.P. Management and survival of female breast cancer. results of a national survey by the American College of Surgeons Cancer. 45:1980;2917-2924
28. Rutqvist L.E., Wallgren A., Nilsson B. Is breast cancer a curable disease? A study of 14, 731 women with breast cancer from the Cancer Registry of Norway. Cancer. 53:1984;1793-1800
29. Fleming I.D., Cooper J.S., Henson D.E., et al. AJCC Cancer Staging Manual. 5th edn. 1997;Lippincott-Raven, Philadelphia
30. Yarbro J.W., Page D.L., Fielding L.P., Partridge E.E., Murphy G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer. 86:1999;2436-2446
31. Tabar L., Vitak B., Chen H.H., et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol. Clin. North Am. 38:2000;625-651
32. Early Breast Cancer Trialists' Collaborative Group Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer. an overview of the randomised trials Lancet. 355:2000;1757-1770
33. Quiet C.A., Ferguson D.J., Weichselbaum R.R., Hellman S. Natural history of node-negative breast cancer. a study of 826 patients with long-term follow-up J. Clin. Oncol. 13:1995;1144-1151
34. Buzdar A.U., Hortobagyi G.N., Singletary S.E., et al. Impact of FAC-adjuvant therapy on mortality of early breast cancer. long-term results of the M.D. Anderson Cancer Center studies Salmon S.E. Adjuvant Therapy of Cancer VIII. 1997;93-100 Lippincott-Raven, Philadelphia
35. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer: M.D. Anderson Cancer Center experience. Surgical Oncology Clinics of North America, 1995, 4, 715-734.
36. Buzdar A.U., Kau S.W., Hortobagyi G.N., et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 69:1992;448-452
37. Quiet C.A., Ferguson D.J., Weichselbaum R.R., Hellman S. Natural history of node-positive breast cancer. the curability of small cancers with a limited number of positive nodes J. Clin. Oncol. 14:1996;3105-3111
38. Thomas E., Buzdar A.U., Hortobagyi G.N., et al. Treatment of locally advanced and inflammatory breast cancer. Singletary S.E., Robb G.L. Advanced Therapy of Breast Disease. 1st edn. 2000;267-280 B.C. Decker, Hamilton (Ontario), Canada
39. Brito R.A., Valero V., Buzdar A.U., et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases. The University of Texas M.D. Anderson Cancer Center experience J. Clin. Oncol. 19:2001;628-633
40. Valagussa P., Zambetti M., Bonadonna G., Zucali R., Mezzanotte G., Veronesi U. Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res. Treat. 15:1990;137-147
41. Jaiyesimi I.A., Buzdar A.U., Hortobagyi G. Inflammatory breast cancer. a review J. Clin. Oncol. 10:1992;1014-1024
42. Hortobagyi G.N., Buzdar A.U. Progress in inflammatory breast cancer. cause for cautious optimism J. Clin. Oncol. 4:1986;1727-1729
43. Ferriere J.P., Assier I., Cure H., et al. Primary chemotherapy in breast cancer. correlation between tumor response and patient outcome Am. J. Clin. Oncol. 21:1998;117-120
44. Ueno N.T., Buzdar A.U., Singletary S.E., et al. Combined-modality treatment of inflammatory breast carcinoma. twenty years of experience at M. D. Anderson Cancer Center Cancer Chemother. Pharmacol. 40:1997;321-329
45. Palangie T., Mosseri V., Mihura J., et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur. J. Cancer. 30A:1994;921-927
46. Chevallier B., Bastit P., Graic Y., et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br. J. Cancer. 67:1993;594-601
47. Henderson I.C., Canellos G.P. Cancer of the breast. the past decade (second of two parts) New Engl. J. Med. 302:1980;78-90
48. Henderson I.C. Chemotherapy of breast cancer. A general overview. Cancer. 51:1983;2553-2559
49. Hendrickson F.R., Lee M.S., Larson M., Gelber R.D. The influence of surgery and radiation therapy on patients with brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 9:1983;623-627
50. Mountain C.F., McMurtrey M.J., Hermes K.E. Surgery for pulmonary metastasis. a 20-year experience Ann. Thorac. Surg. 38:1984;323-330
51. Girard P., Baldeyrou P., le Chevalier T., et al. Surgery for pulmonary metastases. Cancer. 74:1994;2791-2797
52. McDonald M.L., Deschamps C., Ilstrup D.M., Allen M.S., Trastek V.F., Pairolero P.C. Pulmonary resection for metastatic breast cancer. Ann. Thorac. Surg. 58:1994;1599-1602
53. Schneebaum S., Walker M.J., Young D., Farrar W.B.and, Minton J.P. The regional treatment of liver metastases from breast cancer. J. Surg. Oncol. 55:1994;26-31, discussion 32
54. Faneyte I.F., Rutgers E.J., Zoetmulder F.A. Chest wall resection in the treatment of locally recurrent breast carcinoma. indications and outcome for 44 patients Cancer. 80:1997;886-891
55. Wronski M., Arbit E., McCormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer. 80:1997;1746-1754
56. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters, R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer who have no evidence of disease. Breast J. 8:2002;2-9
57. Holmes F.A., Buzdar A.U., Kau S.W., et al. Combined-modality approach for patients with isolated recurrences of breast cancer (IV-NED) - The M.D. Anderson Experience. Breast Dis. 7:1994;7-20
58. Buzdar A.U., Blumenschein G.R., Smith T.L., et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J. Surg. Oncol. 12:1979;27-40
59. Blumenschein G.R., Buzdar A.U., Tashima C.K., Hortobagyi G.N., Gutterman J.U. Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer. Salmon S.E., Jones S.E. Adjuvant Therapy of Cancer. 1977;147-152 Elsevier North-Holland, Amsterdam, The Netherlands
60. Hortobagyi G.N., Smith T.L., Legha S.S., et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J. Clin. Oncol. 1:1983;776-786
61. Swenerton K.D., Legha S.S., Smith T., et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 39:1979;1552-1562
62. Rahman Z.U., Frye D.K., Smith T.L., et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy - a reference. Cancer. 85:1999;104-111
63. Greenberg P.A., Hortobagyi G.N., Smith T.L., Ziegler L.D., Frye D.K., Buzdar A.U. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14:1996;2197-2205
64. Cristofanilli M., Hortobagyi G.N. New Horizons in Treating Metastatic Disease. Clin. Breast Cancer. 1:2001;20-31
65. Hortobagyi G.N. Developments in chemotherapy of breast cancer. Cancer. 88:2000;3073-3079
66. Hortobagyi G.N., Hung M.C., Buzdar A.U. Recent developments in breast cancer therapy. Semin. Oncol. 26:1999;11-20
67. Grizzle W.E., Myers R.B., Arnold M.M., Srivastava S. Evaluation of biomarkers in breast and prostate cancer. J. Cell. Biochem. Suppl. 19:1994;259-266
68. Kelloff G.J., Boone C.W., Crowell J.A., Steele V.E., Lubet R., Doody L.A. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J. Cell. Biochem. Suppl. 19:1994;1-9
69. Kelloff G.J., Boone C.W., Steele V.E. Progress in cancer chemoprevention. perspectives on agent selection and short-term clinical intervention trials Cancer Res. 54:1994;2015S-2024S
70. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 81:1989;1879-1886
71. Andersson M., Storm H.H., Mouridsen H.T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. Natl. Cancer Inst. 83:1991;1013-1017
72. Fornander T., Rutqvist L.E., Cedermark B., et al. Adjuvant tamoxifen in early breast cancer. occurrence of new primary cancers Lancet. 1:1989;117-120
73. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Cancer Inst. 87:1995;645-651
74. Chang J., Powles T.J., Ashley S.E., et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann. Oncol. 7:1996;671-675
75. Powles T.J., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absoptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14:1996;78-84
76. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer. an overview of the randomized trials Lancet. 351:1998;1451-1467
77. Fisher B., Joseph P., Costantino D., et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 90:1998;1371-1388
78. Powles T.J., Jones A.L., Ashley S.E., et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat. 31:1994;73-82
79. Camerini T., Mariani L., De Palo G., et al. Safety of the synthetic retinoid fenretinide. long-term results from a controlled clinical trial for the prevention of contralateral breast cancer J. Clin. Oncol. 19:2001;1664-1670
80. IBIS investigators First results from the International Breast Cancer Intervention Study (IBIS-I). a randomised prevention trial Lancet. 360:2002;817-824
81. Bonanni B., Veronesi U. The Italian tamoxifen prevention trial. Dis. Markers. 15:1999;199-200
82. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen. preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study Lancet. 352:1998;93-97
83. Anzano M.A., Peer C.W., Smith J.M., et al. Chemoprevention of mammary carcinogenesis in the rat. combined use of raloxifene and 9-cis-retinoic acid J. Natl. Cancer Inst. 88:1996;123-125
84. Boss S.M., Huster W.J., Neild J.A., Glant M.D., Eisenhut C.C., Draper M.W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol. 177:1997;1458-1464
85. Gradishar W.J., Jordan V.C. Clinical potential of new antiestrogens. J. Clin. Oncol. 15:1997;840-852
86. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifen on risk of breast cancer in postmenopausal women. results from the MORE randomized trial. Multiple outcomes of raloxifen evaluation JAMA. 281:1999;2189-2197
87. Cummings S.R., Norton L., Eckert S., et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. Proc. Am. Soc. Clin. Oncol. 17:1998;2a. (abstr 3)
88. Delia D., Aillo A., Formelli F., et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl)retinamide and effect of deregulated bcl-2. Blood. 85:1995;359-367
89. Lotan R. Retinoids and apoptosis. implications for cancer chemoprevention and therapy J. Natl. Cancer Inst. 87:1995;1655-1657
90. Sporn M.B., Roberts A.B. Role of retinoids in differentiation and carcinogenesis. Cancer Res. 43:1983;3034-3040
91. Mangelsdorf D.J., Umesono K., Evans R.M. The retinoid receptors. Sporn M.B., Roberts A.B., Goodman D.S. The Retinoids: Biology, Chemistry, and Medicine. 2nd edn. 1994;319-349 Raven Press, New York
92. Pasquali D., Bellastella A., Valente A., et al. Retinoic acid receptors alpha, beta and gamma, and cellular retinol binding protein-I expression in breast fibrocystic disease and cancer. Eur. J. Endocrinol. 137:1997;410-414
93. Bishoff E.D., Gottardis M.M., Moon T.E., Heyman R.A., Lamph W.W. Beyond tamoxifen. the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma Cancer Res. 53:1998;479-484
94. Toma S., Isnardi L., Raffo P., et al. Effects of ALL-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines. growth inhibition and apoptosis induction Int. J. Cancer. 70:1997;619-627
95. De Palo G., Camerini T., Marubini E., et al. Chemoprevention trial of contralateral breast cancer with fenretinamide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori. 83:1997;884-894
96. De Palo G., Veronesi U., Camerini T., et al. Can fenretinide protect women against ovarian cancer? J. Natl. Cancer Inst. 87:1995;146-147
97. Cancer Incidence in Five Continents. Age-standardized Incidence Rates, Four-digit Rubrics, and Age-standardized and Cumulative Incidence Rates, Three-digits Rubrics. IARC Science Publication No. 120. Lyon, IARC, 1992, 871-1011.
98. Mariani L., Formelli F., De Palo G., et al. Chemoprevention of breast cancer with fenretinide (4-HPR). study of long-term visual and ophtalmologic tolerability Tumori. 82:1996;444-449
99. National Cancer Institute Annual Cancer Statistics Review including Cancer Trends: 1950-1985. 1988;US Department of Health and Human Services, Bethesda, MD
100. Lu L.J., Anderson K.E., Grady J.J., Kohen F., Nagamani M. Decreased ovarian hormones during a soya diet. implications for breast cancer prevention Cancer Res. 60:2000;4112-4121
101. Rose D.P., Connolly J.M., Liu X.H. Dietary fatty acids and human breast cancer cell growth, invasion, and metastasis. Adv. Exp. Med. Biol. 364:1994;83-91
102. Wynder E.L., Cohen L.A., Muscat J.E., Winters B., Dwyer J.T., Balckburn G. Breast cancer. weighing the evidence for a promoting role of dietary fat J. Natl. Cancer Inst. 89:1997;766-775
103. Boyd N.F., Greenberg C., Lockwood G., et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast. results from a randomized trial J. Natl. Cancer Inst. 89:1997;488-496
104. Chlebowski R.T., Blackburn G.L., Buzzard J.M., et al. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. J. Clin. Oncol. 11:1993;2072-2080
105. Willett W.C., Stampfer M.J. Sobering data on alcohol and breast cancer. Epidemiology. 8:1997;225-227
106. Nelson H., Miller S.H., Buck D., Demuth R.J., Fletcher W.S., Buehler P. Effectiveness of prophylactic mastectomy in the prevention of breast tumors in C3H mice. Plast. Reconstr. Surg. 83:1989;662-669
107. Temple W.J., Lindsay R.L., Magi E., Urbanski S.J. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am. J. Surg. 161:1991;413-415
108. Wong J.H., Jackson C.F., Swanson J.S., et al. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7, 12-dimethylbenzanthracene-induced breast cancer. Surgery. 90:1986;67-71
109. Pennisi V.R., Capozzi A. Subcutaneous mastectomy data. a final statistical analysis of 1500 patients Plast. Surg. 13:1989;15-21
110. Woods J.E., Meland N.B. Conservative management in full-thickness nipple-areolar necrosis after subcutaneous mastectomy. Plast. Reconstr. Surg. 84:1989;258-264
111. Krainer M., Silva-Arrieta S., FitzGerald M.G., et al. Differential contributions of BRCA1 and BRCA2 to early onset breast cancer. New Engl. J. Med. 336:1997;1416-1421
112. Stark A., Hulka B.S., Joens S., et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J. Clin. Oncol. 18:2000;267-274
113. Schrag D., Kuntz K.M., Garber J.E., Weeks J.C. Decision analysis. effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations N. Engl. J. Med. 336:1997;1465-1471
114. Lynch H.T., Lemon S.J., Durham C., et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79:1997;2219-2228
115. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340:1999;77-84
116. Bilimoria M.M., Morrow M. The woman at increased risk for breast cancer. evaluation and management strategies CA Cancer J. Clin. 45:1995;263-278
117. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. New Engl. J. Med. 346:2002;1660-1662
118. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New Eng. J. Med. 346:2002;1609-1615
119. Rebbeck T.R., Lynch H.T., Neuhausen S.L. The prevention and observation of surgical end points study group, 2002, Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl. J. Med. 346:2002;1616-1622